145 related articles for article (PubMed ID: 23099332)
1. A novel synthetic bipartite carrier protein for developing glycotope-based vaccines.
Chiang HL; Lin CY; Jan FD; Lin YS; Hsu CT; Whang-Peng J; Liu LF; Nieh S; Lin CC; Hwang J
Vaccine; 2012 Dec; 30(52):7573-81. PubMed ID: 23099332
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope.
Lo-Man R; Vichier-Guerre S; Bay S; Dériaud E; Cantacuzène D; Leclerc C
J Immunol; 2001 Feb; 166(4):2849-54. PubMed ID: 11160353
[TBL] [Abstract][Full Text] [Related]
3. SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade.
Fassò M; Waitz R; Hou Y; Rim T; Greenberg NM; Shastri N; Fong L; Allison JP
Proc Natl Acad Sci U S A; 2008 Mar; 105(9):3509-14. PubMed ID: 18303116
[TBL] [Abstract][Full Text] [Related]
4. A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer.
Klyushnenkova EN; Kouiavskaia DV; Parkins CJ; Caposio P; Botto S; Alexander RB; Jarvis MA
J Immunother; 2012 Jun; 35(5):390-9. PubMed ID: 22576344
[TBL] [Abstract][Full Text] [Related]
5. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
Timmerman JM; Levy R
J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
[TBL] [Abstract][Full Text] [Related]
6. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC; Abrams JT; Zhang SY; Galili U
Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
[TBL] [Abstract][Full Text] [Related]
7. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas.
Betting DJ; Kafi K; Abdollahi-Fard A; Hurvitz SA; Timmerman JM
J Immunol; 2008 Sep; 181(6):4131-40. PubMed ID: 18768870
[TBL] [Abstract][Full Text] [Related]
8. APC-Targeted DNA Vaccination Against Reticulocyte-Binding Protein Homolog 5 Induces
Bjerkan L; Visweswaran GRR; Gudjonsson A; Labbé GM; Quinkert D; Pattinson DJ; Spång HCL; Draper SJ; Bogen B; Braathen R
Front Immunol; 2021; 12():720550. PubMed ID: 34733274
[TBL] [Abstract][Full Text] [Related]
9. Enhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cells.
Betting DJ; Mu XY; Kafi K; McDonnel D; Rosas F; Gold DP; Timmerman JM
Vaccine; 2009 Jan; 27(2):250-9. PubMed ID: 19000731
[TBL] [Abstract][Full Text] [Related]
10. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
11. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in mice.
Xiao L; Joo KI; Lim M; Wang P
PLoS One; 2012; 7(11):e48866. PubMed ID: 23139820
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity.
Rohrbach F; Weth R; Kursar M; Sloots A; Mittrücker HW; Wels WS
J Immunol; 2005 May; 174(9):5481-9. PubMed ID: 15843546
[TBL] [Abstract][Full Text] [Related]
14. A cancer therapeutic vaccine based on clustered Tn-antigen mimetics induces strong antibody-mediated protective immunity.
Richichi B; Thomas B; Fiore M; Bosco R; Qureshi H; Nativi C; Renaudet O; BenMohamed L
Angew Chem Int Ed Engl; 2014 Oct; 53(44):11917-20. PubMed ID: 25168881
[TBL] [Abstract][Full Text] [Related]
15. Resolving conflicting data on expression of the Tn antigen and implications for clinical trials with cancer vaccines.
Li Q; Anver MR; Butcher DO; Gildersleeve JC
Mol Cancer Ther; 2009 Apr; 8(4):971-9. PubMed ID: 19372570
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
17. Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice.
Saif JM; Vadakekolathu J; Rane SS; McDonald D; Ahmad M; Mathieu M; Pockley AG; Durrant L; Metheringham R; Rees RC; McArdle SE
Eur J Immunol; 2014 Apr; 44(4):994-1004. PubMed ID: 24338683
[TBL] [Abstract][Full Text] [Related]
18. Valency and density matter: Deciphering impacts of immunogen structures on immune responses against a tumor associated carbohydrate antigen using synthetic glycopolymers.
Qin Q; Yin Z; Wu X; Haas KM; Huang X
Biomaterials; 2016 Sep; 101():189-98. PubMed ID: 27294537
[TBL] [Abstract][Full Text] [Related]
19. Mapping T and B cell epitopes in sperm protein 17 to support the development of an ovarian cancer vaccine.
Xiang SD; Gao Q; Wilson KL; Heyerick A; Plebanski M
Vaccine; 2015 Nov; 33(44):5950-9. PubMed ID: 26263201
[TBL] [Abstract][Full Text] [Related]
20. A fully synthetic therapeutic vaccine candidate targeting carcinoma-associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates.
Lo-Man R; Vichier-Guerre S; Perraut R; Dériaud E; Huteau V; BenMohamed L; Diop OM; Livingston PO; Bay S; Leclerc C
Cancer Res; 2004 Jul; 64(14):4987-94. PubMed ID: 15256473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
